CenterWatch and Plutus Capital Partners have launched Clinical Trials Quarterly, a co-branded newsletter for the contract research organization (CRO) industry that expands CenterWatch’s reach to financial clients in Asia and Europe.
The quarterly newsletter, with an initial distribution base of over 700, covers CROs, with a particular focus on the financial and business aspects of the industry.
Each issue will feature an M&A Tracker of all of the quarter’s biggest CRO mergers and acquisitions, a recap of the quarter’s CRO strategic partnerships, top headlines and news on R&D trends. It also will include interviews with industry insiders and a look at top pharmaceutical and biotechnology company drug development pipelines.
“This partnership leverages Plutus’ deal experience and network in the CRO space, with CenterWatch’s industry insights, so as to provide companies with access to information that can guide their strategic objectives,” said Ripun Jai Mehta, managing partner, Plutus Capital Partners.
“This strategic collaborative partnership with Plutus Capital provides us the opportunity to share clinical trials content with the financial community in Asia and Europe, who are tracking all activity within the industry,” said Joan Chambers, chief operating officer of CenterWatch. “In a time of increased M&As and strategic partnerships, it’s important to keep all industry stakeholders well informed—this collaboration provides that opportunity for Plutus Capital and CenterWatch.”